Amblyotech Inc.

Amblyotech is using an iPad as a syringe to administer a novel therapy for the treatment of Amblyopia, a condition that affects 9 million people in the US.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Boston, MA, US
  • Currency USD
  • Founded August 2014
  • Employees 2
  • Incorporation Type Not Incorporated
  • Website amblyotech.com

Company Summary

Amblyotech is developing a novel, patented treatment for Amblyopia. This ocular condition commonly known as "Lazy Eye" affects 3% of the global population and for which there is no effective treatment for adults. Amblyotech has developed in partnership with Ubisoft a "game" therapy which has been shown in clinical trials to be 90% effective in regaining binocular function.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free